ABSTRACT
INTRODUCTION The number of chemotherapeutic agents available to treat patients with cancer has expanded rapidly in recent years. In addition to traditional cytotoxic agents, new anticancer therapies now exist in the form of monoclonal antibodies, small molecule signal transduction inhibitors, hormonal agents, and immunologic modulators. As more patients are treated aggressively with a wide range of agents, both alone and in combination, the range of possible neurotoxicities directly from anticancer therapy has expanded as well. This chapter will review the mechanism, spectrum, and treatment of neurotoxicity due to conventional chemotherapies, monoclonal antibodies, and small molecule inhibitors used in the treatment of patients with cancer.
